1,7-naphthyridine 1-oxides as novel potent and selective inhibitors of p38 mitogen activated protein kinase

Journal of Medicinal Chemistry

Volumn 54, Issue 22, 2011, Pages 7899-7910

  Lumeras, Wenceslao ^a   Vidal, Laura ^a   Vidal, Bernat ^a   Balagué, Cristina ^a   Orellana, Adelina ^a   Maldonado, Mãnica ^a   Domãnguez, Marãa ^a   Segarra, Vãctor ^b   Caturla, Francisco ^a  

^a Department of Medicinal Chemistry ^*  (Spain)

^b Department of Biology ^*  (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

1,7 NAPHTHYRIDINE 1 OXIDE DERIVATIVE; 2 (1 ACETYLPIPERIDIN 4 YL) 4 (2 CHLOROPHENYL) 8 (2,6 DIFLUOROPHENYL) 1,7 NAPHTHYRIDINE 7 OXIDE; 4 (2 CHLORO 4 FLUOROPHENYL) 8 (2,6 DICHLOROPHENYL) 1,7 NAPHTHYRIDINE 7 OXIDE; 4 (2 CHLORO 4 FLUOROPHENYL) 8 (2,6 DICHLOROPHENYL) 2 (1 METHYLPIPERIDIN 4 YL) 1,7 NAPHTHYRIDINE 7 OXIDE; 4 (2 CHLOROPHENYL) 8 (2,6 DICHLOROPHENYL) 1,7 NAPHTHYRIDINE 7 OXIDE; 4 (2 CHLOROPHENYL) 8 (2,6 DICHLOROPHENYL) 2 (2 ETHOXYETHOXY) 1,7 NAPHTHYRIDINE 7 OXIDE; 4 (2 CHLOROPHENYL) 8 (2,6 DIFLUOROPHENYL) 2 PIPERIDIN 4 YL 1,7 NAPHTHYRIDINE 7 OXIDE; 4 (2,4 DIFLUOROPHENYL) 8 (2 METHOXYPHENYL) 1,7 NAPHTHYRIDINE 7 OXIDE; 4 (2,4 DIFLUOROPHENYL) 8 (2 METHYLPHENYL) 1,7 NAPHTHYRIDINE 7 OXIDE; 5 (2,6 DICHLOROPHENYL) 2 (2,4 DIFLUOROPHENYLTHIO)PYRIMIDO[1,6 B]PYRIDAZIN 6 ONE; 8 (2 CHLOROPHENYL) 4 (2,4 DIFLUOROPHENYL) 1,7 NAPHTHYRIDINE 7 OXIDE; 8 (2,6 DICHLOROPHENYL) 4 ARYL 1,7 NAPHTHYRIDINE 7 OXIDE; 8 (2,6 HALOPHENYL) 4 ARYL 2 (PIPERIDIN 4 YL) 1,7 NAPHTHYRIDINE 7 OXIDE; DORAMAPIMOD; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADJUVANT ARTHRITIS; AEROBIC METABOLISM; AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CATALYSIS; CHO CELL; COMPETITIVE INHIBITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYCLIZATION; CYTOKINE PRODUCTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; HYDROGEN BOND; HYDROPHOBICITY; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, EXPERIMENTAL; BINDING SITES; CELL LINE; CRYSTALLOGRAPHY, X-RAY; HUMANS; INFLAMMATION; LIPOPOLYSACCHARIDES; MALE; MICE; MICROSOMES, LIVER; MONOCYTES; NAPHTHYRIDINES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN BINDING; PROTEIN CONFORMATION; RATS; RATS, WISTAR; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR NECROSIS FACTOR-ALPHA;

EID: 81555218659     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm200975u     Document Type: Article

References (29)

1. Han, J.; Lee, J. D.; Bibbs, L.; Ulevitch, R. J. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells Science 1994, 265, 808-811 (Pubitemid 24266145)
2. Raingeaud, J.; Gupta, S.; Rogers, J. S.; Dickens, M.; Han, J.; Ulevitch, R. J.; Davis, R. J. Characterization of the structure and function of a novel MAP kinase kinase (MKK6) J. Biol. Chem. 1996, 271, 2886-2891
3. Raingeaud, J.; Whitmarsh, A. J.; Barrett, T.; Derijard, B.; Davis, R. J. MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway Mol. Cell. Biol. 1996, 16, 1247
4. Badger, A. M.; Bradbeer, J. N.; Votta, B.; Lee, J. C.; Adams, J. L.; Griswold, D. E. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function J. Pharmacol. Exp. Ther. 1996, 279, 1453-1461 (Pubitemid 27166795)
5. Feldmann, M.; Brennan, F. M.; Maini, R. N. Role of cytokines in rheumatoid arthritis Annu. Rev. Immunol. 1996, 14, 397-440 (Pubitemid 26130190)
6. Rutgeerts, P.; D'Haens, G.; Targan, S.; Vasiliauskas, E.; Hanauer, S. B.; Present, D. H.; Mayer, L.; van Hogezand, R. A.; Braakman, T.; DeWoody, K. L. Efficacy and safety of retreatment with anti-tumour necrosis factor antibody (Infliximab) to maintain remission in Chron's disease Gastroenterology 1999, 117, 761-769 (Pubitemid 29468216)
7. Foster, M. L.; Halley, F.; Souness, J. E. Potential of p38 inhibitors in the treatment of rheumatoid arthritis Drug News Perspect. 2000, 13, 488-497 (Pubitemid 32063588)
8. Kumar, S.; Boehm, J.; Lee, J. C. p38 MAP kinases: key signaling molecules as therapeutic targets for inflammatory diseases Nat. Rev. Drug Discovery 2003, 2, 717-726 (Pubitemid 37361787)
9. Mayer, R. J.; Callahan, J. F. p38 MAP kinase inhibitors: A future therapy for inflammatory diseases Drug Discovery Today: Ther. Strategies 2006, 3 (1) 49-54
10. Lee, J. C.; Laydon, J. T.; McDonnell, P. C.; Gallagher, T. F.; Kumar, S.; Green, D.; McNulty, D.; Blumenthal, M. J.; Heyes, J. R.; Landvatter, S. W.; Strickler, J. E.; McLaughlin, M. M.; Siemens, I. R.; Fisher, S. M.; Livi, G. P.; White, J. R.; Adams, J. L.; Young, P. R. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis Nature 1994, 372, 739-746
11. Weisman, M.; Furst, D.; Schiff, M.; Kauffman, R.; Merica, E.; Martin-Munley, S. FRI0018 a double-blind, placebo controlled trial of VX-745, an oral p38 MAP kinase inhibitor, in patients with rheumatoid arthritis (RA). Ann. Rheum. Dis. 2002, 61 (Suppl. 1).
12. Goldstein, D. M.; Kuglstatter, A.; Lou, Y.; Soth, M. J. J. Med. Chem. 2010, 53, 2345-2353
13. Ferraciola, G. F. VX-745 Vertex Pharmaceuticals Curr. Opin. Anti-Inflammatory Immunomodulatory. Invest. Drugs 2000, 2, 74-77
14. Haddad, J. J. VX-745 (Vertex Pharmaceuticals) Curr. Opin. Invest. Drugs 2001, 2, 1070-1076
15. Cohen, S. B.; Cheng, T. T.; Chindalore, V.; Damjanov, N.; Burgos-Vargas, R.; Delora, P.; Zimany, K.; Travers, H.; Caulfield, J. P. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis Arthritis Rheum. 2009, 60 (2) 335-44
16. Fitzgerald, C. E.; Patel, S. B.; Becker, J. W.; Cameron, P. M.; Zaller, D.; Pikounis, V. B.; O'Keefe, S. J.; Scapin, G. Nat. Struct. Biol. 2003, 10, 764
17. Natarajan, S. R.; Heller, S. T.; Nam, K.; Singh, S. B.; Scapin, G.; Patel, S.; Thompson, J. E.; Fitzgerald, C. E.; O'Keefe, S. J. Bioorg. Med. Chem. Lett. 2006, 16 (22) 5809
18. Fitzgerald, C. E.; Patel, S. B.; Becker, J. W.; Cameron, P. M.; Zaller, D.; Pikounis, V. B.; O'Keefe, S. J.; Scapin, G. Structural basis for p38 MAP kinase quinazolinone and pyrido-pyrimidine inhibitor specificity Nat. Struct. Biol. 2003, 10, 764-769 (Pubitemid 37052417)
19. Lumeras, W.; Caturla, F.; Vidal, L.; Esteve, C.; Balagué, C.; Orellana, A.; Dominguez, M.; Roca, R.; Huerta, J. M.; Godessart, N.; Vidal, B. Design, synthesis and structure-activity relationships of aminopyridine N -oxides, a novel scaffold for the potent and selective inhibition of p38 mitogen activated protein kinase J. Med. Chem. 2009, 52, 5531-5545
20. Hunt, J. A.; Kallashi, F.; Ruzek, R. D.; Sinclair, P. J.; Ita, I.; McCormick, S. X.; Pivnichny, J. V.; Hop, C. E. C.; Kumar, S.; m Wang, Z.; O'Keefe, S. J.; O'Neill, E. A.; Porter, G.; Thompson, J. E.; Woods, A.; Zaller, D. M.; Doherty, J. B. p38 inhibitors: piperidine- and 4-aminopiperidine- substituted naphthyridinones, quinolinones, and dihydroquinazolinones Bioorg. Med. Chem. Lett. 2003, 13, 467-470 (Pubitemid 36259715)
21. Bao, J.; Hunt, J. A.; Miao, S.; Rupprecht, K. M.; Stelmach, J. E.; Liu, L.; Ruzek, R. D.; Sinclair, P. J.; Pivnichny, J. V.; Hop, C. E. C. A.; Kumar, S.; Zaller, D. M.; Shoop, W. L.; O'Neill, E. A.; O'keefe, S. J.; Thompson, C. M.; Cubbon, R. M.; Wang, R.; Zhang, W. X.; Thompson, J. E.; Doherty, J. B. p38 MAP kinase inhibitors: metabolically stabilized piperidine-substituted quinolinones and naphthyridinones Bioorg. Med. Chem. Lett. 2006, 16, 64-68 (Pubitemid 41625642)
22. Alonso-Alija, C.; Michels, M.; Schirok, H.; Schlemmer, K.-H.; Bell, J.; Fitzgerald, M. F.; Dodd, S.; Gill, A. Monocyclic Aroylpyridinones as Antiinflammatory Agents. WO03076405, September 2003.
23. Schirok, H.; Alonso-Alija, C.; Benet-Buchholz, J.; Göller, A. H.; Grosser, R.; Michels, M.; Paulsen, H. Efficient regioselective synthesis of 6-amino-5-benzoyl-1-substituted 2(1 H)-pyridinones J. Org. Chem. 2005, 70, 9463-9469 (Pubitemid 41611702)
24. Manske, R. H. Chem. Rev. 1942, 30, 113
25. Bergstrom, F. W. Chem. Rev. 1944, 35, 77
26. Cheng, C. C.; Yan, S. J. Org. React. 1982, 28, 37
27. Wang, Z.; Canagarajah, B. J.; Boehm, J. C.; Kassisa, S.; Cobb, M. H.; Young, P. R.; Abdel-Meguid, S.; Adams, J. L.; Goldsmith, E. J. Structural basis of inhibitor selectivity in MAP kinases Structure (London) 1998, 6, 1117-1128 (Pubitemid 28434115)
28. Zimmiti, C. S.; Schwartz, R.; Torcellini, C. A.; Pargellis, C. A.; Madwed, J. B.; Weldon, S. M. Suppression of p38 activity in vitro and THF alpha production in vivo with BIRB-796 BS, a novel p38 kinase inhibitor Arthritis Rheum. 2001, 44, S114
29. Regan, J.; Capolino, A.; Cirillo, P. F.; Gilmore, T.; Graham, A. G.; Hickey, E.; Kroe, R. R.; Madwed, J.; Moriak, M.; Nelson, R.; Pargellis, C. A.; Swinamer, A.; Torcellini, C.; Tsang, M.; Moss, N. Structure-activity- relationships of the p38 MAP kinase inhibitor 1-(5- tert -butyl-2- p -tolyl-2 H -pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)napthalen-1-yl]urea (BIRB-796) J. Med. Chem. 2003, 46, 4676-4686